Harvard's Dr. Fatima Cody Stanford and psychologist Supatra Tovar explain why shared support can matter on Ozempic or Zepbound, plus what makes a good buddy.
Recap by typeshit. Full story at health.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
Researchers report that asprosin, a hunger hormone released by fat tissue, stays elevated after weight loss, which could help explain why lost pounds come back.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
Loading…